<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294252</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2016-03</org_study_id>
    <nct_id>NCT03294252</nct_id>
  </id_info>
  <brief_title>Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers</brief_title>
  <acronym>PIPOX</acronym>
  <official_title>Phase I / II Dose Escalation of Oxaliplatin Via a Laparoscopic Approach of Aerosol Pressurized Intraperitoneal Chemotherapy for Nonresectable Peritoneal Metastases of Digestive Cancers (Stomach, Hail and Colorectal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current curative treatment of digestive peritoneal carcinomatosis consists of complete&#xD;
      cytoreduction surgery associated with intraperitoneal chemotherapy. This treatment has&#xD;
      important limits: a high morbimortality and the impossibility of repeating the sessions. The&#xD;
      majority of patients are therefore treated with systemic chemotherapy, which despite its&#xD;
      progress, remains palliative.&#xD;
&#xD;
      Pressurized Intraperitoneal aerosol chemotherapy (PIPAC) has many advantages: under&#xD;
      laparoscopy, low morbidity, good intratumoral penetration of cytotoxics, possibility of&#xD;
      repeating the sessions and low financial cost.&#xD;
&#xD;
      Therefore, the investigator propose a phase 1 study, in colorectal and stomach cancer, with&#xD;
      oxaliplatin doses escalation in Pressurized Intraperitoneal aerosol chemotherapy. It would&#xD;
      allow a better tumor response, with potentially few risks and thus improve survival in&#xD;
      patients with digestive peritoneal carcinoses, increasing access to cytoreductive surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">June 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximal Tolerated Dose</measure>
    <time_frame>8 to 12 weeks</time_frame>
    <description>maximal tolerated dose 3x3 patients inclusion(modified fibonacci dose escalation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative toxicity after the end of the CIPPA sessions received (maximum 5) at the same dose level</measure>
    <time_frame>24 months</time_frame>
    <description>with CTC-AE scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Digestive Cancer</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental drugs used in this protocol are Oxaliplatin, 5-Fluorouracil and L-Folinic acid. All are used as part of their marketing authorization, with the exception of Oxaliplatin as regards its mode of administration specific to the CIPPA procedure (injection and nebulisation in intraperitoneal).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before CIPPA.</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Folinic acid</intervention_name>
    <description>Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before CIPPA.</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
    <other_name>ELVORIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age ≥ 18 years&#xD;
&#xD;
          2. Histological or cytological diagnosis of peritoneal carcinoma of colorectal, gastric&#xD;
             or gray primitive&#xD;
&#xD;
          3. Having previously received at least 3 months of systemic chemotherapy for metastatic&#xD;
             disease (type of chemotherapy left to the discretion of each investigator). Patients&#xD;
             who received chemotherapy with bevacizumab (Avastin®) more than 2 months ago may be&#xD;
             included.&#xD;
&#xD;
          4. Irritable or extensive peritoneal carcinosis:&#xD;
&#xD;
             Extended peritoneal carcinoma of gastric adenocarcinoma (PCI score&gt; 5) Extended&#xD;
             peritoneal carcinoma of adenocarcinoma (PCI score&gt; 13) Extended peritoneal carcinoma&#xD;
             of colorectal adenocarcinoma (PCI score&gt; 15)&#xD;
&#xD;
          5. ECOG performance index &lt; or = 2 (see Annex 8)&#xD;
&#xD;
          6. Life expectancy&gt; 3 months&#xD;
&#xD;
          7. Peripheral neuropathy grade ≤ 1&#xD;
&#xD;
          8. Hematological function: Hemoglobin ≥ 9 g / dL, leukocytes ≥ 4000 / mm3, PNN ≥ 1500 /&#xD;
             mm3, platelets ≥ 100 000 / mm3&#xD;
&#xD;
          9. creatinine clearance&gt; 50 mL / min (cockcroft and Gault formula)&#xD;
&#xD;
         10. Hepatic function: Total bilirubin ≤ 1.5 x ULN, ASAT and ALAT ≤ 3 x ULN, Alkaline&#xD;
             phosphatases ≤ 3 x ULN&#xD;
&#xD;
         11. Patient without deficiency or with partial deficiency in Dihydropyrimidine&#xD;
             dehydrogenase (i.e. DPD)&#xD;
&#xD;
         12. Effective contraception for women of childbearing age&#xD;
&#xD;
         13. Informing the patient and obtaining free, informed and written consent signed by the&#xD;
             patient and his / her investigator.&#xD;
&#xD;
         14. Affiliated subject or beneficiary of the social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who received bevacizumab (Avastin®) less than 2 months ago can not be&#xD;
             included&#xD;
&#xD;
          2. Extra-peritoneal metastases, except for less than 3 pulmonary nodules (each size &lt;5mm)&#xD;
&#xD;
          3. Known hypersensitivity to Oxaliplatin&#xD;
&#xD;
          4. Complete deficiency of Dihydropyrimidine dehydrogenase (i.e. DPD)&#xD;
&#xD;
          5. Grade 1&gt; grade 1 peripheral neuropathy due to or not with Oxaliplatin previously used&#xD;
&#xD;
          6. Active active or other serious underlying disease that may prevent the patient from&#xD;
             receiving treatment&#xD;
&#xD;
          7. Intracranial or intraocular hypertension (ongoing at the time of inclusion)&#xD;
&#xD;
          8. Severe or Severe Heart Failure (ongoing at the time of inclusion)&#xD;
&#xD;
          9. Complete intestinal obstruction (ongoing at the time of inclusion)&#xD;
&#xD;
         10. Other concurrent cancer or history of cancer other than in situ cancer of treated&#xD;
             cervix or basal cell carcinoma or squamous cell carcinoma&#xD;
&#xD;
         11. Pregnant or nursing women&#xD;
&#xD;
         12. Persons deprived of their liberty or under guardianship or unable to give their&#xD;
             consent&#xD;
&#xD;
         13. Inability to submit to medical follow-up of the trial for geographical, social or&#xD;
             psychological reasons&#xD;
&#xD;
         14. Long-term corticosteroids (duration&gt; 3 months), except for weaning for at least 3&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DUMONT Frederic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DUMONT Frederic, MD</last_name>
    <phone>+33 2 40 67 99 00</phone>
    <email>frederic.dumont@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DEBEAUPUIS Emilie</last_name>
    <phone>+33 2 40 67 99 00</phone>
    <email>emilie.debeaupuis@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoual BAKRIN, MD</last_name>
      <email>naoual.bakrin@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DUMONT Frédéric, MD</last_name>
      <phone>+33 2 40 67 99 00</phone>
      <email>frederic.dumont@ico.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIPAC</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>peritoneal metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

